retro.jpg
Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting
May 06, 2019 12:57 ET | Retrotope
LOS ALTOS, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today positive findings from an expanded access study of the company’s lead candidate, RT001, in a patient with LOTS, as...
retro.jpg
EMA Grants Orphan Medicinal Product Designation for Retrotope’s RT001 in the Treatment of Infantile Neuroaxonal Dystrophy (INAD), a PLA2G6 associated neurodegeneration (PLAN)
March 13, 2019 13:23 ET | Retrotope
LOS ALTOS, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Retrotope received notification from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) that its request for...
retro.jpg
UPDATE - Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)
December 14, 2018 15:50 ET | Retrotope
LOS ALTOS, Calif., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today that it has begun enrollment of the first patients and has started dosing of infants with the ultra-rare...
retro.jpg
Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)
December 13, 2018 12:16 ET | Retrotope
LOS ALTOS, Calif., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today that it has begun enrollment of the first patients and has started dosing of infants with the ultra-rare...
retro.jpg
Retrotope Presents Data Demonstrating Arrest of Disease Progression with Treatment of RT001 in Patients with Infantile Neuroaxonal Dystrophy (INAD)
October 15, 2018 07:30 ET | Retrotope
Results presented at the 2018 National Organization for Rare Disorders (NORD) Rare Diseases & Orphan Products Breakthrough Summit® LOS ALTOS, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) --...
retro.jpg
Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients
October 04, 2018 08:00 ET | Retrotope
SUNNYVALE and LOS ALTOS, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Parkinson’s Institute and Clinical Center, which provides comprehensive patient care, while discovering new treatment options to...
retro.jpg
Retrotope Announces the Initiation of Expanded Access (Compassionate Use) Trial of RT001 in Amyotrophic Lateral Sclerosis (ALS)
September 17, 2018 08:00 ET | Retrotope
First ALS patient dosed with RT001 LOS ALTOS, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Retrotope today announced that it has supplied its drug RT001 for the initiation of an expanded access (EA)...
retro.jpg
Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate
July 09, 2018 08:00 ET | Retrotope
LOS ALTOS, Calif. and LOS ANGELES, July 09, 2018 (GLOBE NEWSWIRE) -- Retrotope and collaborators led by Dr. Marie-Francoise Chesselet, the Charles H. Markham Professor of Neurology, and Interim...
retro.jpg
Retrotope Receives FDA Clearance to Commence RT001 Phase 2/3 Clinical Trial in Patients with Infantile Neuroaxonal Dystrophy (INAD)
June 28, 2018 08:00 ET | Retrotope
Patient enrollment anticipated to start in July 2018 LOS ALTOS, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration (FDA) has granted the...
retro.jpg
Retrotope Announces the Initiation of Expanded Access (Compassionate Use) Trials of RT001 in Two Neurodegenerative Disorders
June 11, 2018 08:00 ET | Retrotope
LOS ALTOS, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today the start of two single-patient, Compassionate Use trials of RT001 at major university medical centers in Late Onset...